The aforementioned 5 genes (AXL, GAB1, ERBB2, NRP2, and ESR1) along with 13 pharmacological agents represent promising candidates for enhancing the treatment of osteoporosis and sarcopenia. This evidence concerns the gene ESR1 and sarcopenia.